Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer
Open Access
- 12 November 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (22), 5654
- https://doi.org/10.3390/ijms20225654
Abstract
Sirtuins, a family of nicotinamide adenine dinucleotide (NAD+)-dependent lysine deacetylases, are promising targets for anticancer treatment. Recently, we characterized a novel pan-sirtuin (SIRT) inhibitor, MC2494, displaying antiproliferative effects and able to induce death pathways in several human cancer cell lines and decrease tumor growth in vivo. Based on the chemical scaffold of MC2494, and by applying a structure–activity relationship approach, we developed a small library of derivative compounds and extensively analyzed their enzymatic action at cellular level as well as their ability to induce cell death. We also investigated the effect of MC2494 on regulation of cell cycle progression in different cancer cell lines. Our investigations indicated that chemical substitutions applied to MC2494 scaffold did not confer higher efficacy in terms of biological activity and SIRT1 inhibition, but carbethoxy-containing derivatives showed higher SIRT2 specificity. The carbethoxy derivative of MC2494 and its 2-methyl analog displayed the strongest enzymatic activity. Applied chemical modifications improved the enzymatic selectivity of these SIRT inhibitors. Additionally, the observed activity of MC2494 via cell cycle and apoptotic regulation and inhibition of cell migration supports the potential role of SIRTs as targets in tumorigenesis and makes SIRT-targeting molecules good candidates for novel pharmacological approaches in personalized medicine.Funding Information
- MIUR (PRIN-20152TE5PK)
- Ministero della Salute (PE-2013-02355271)
- AIRC- (17217, 19162)
This publication has 38 references indexed in Scilit:
- Cancer epigenetics: Moving forwardPLoS Genetics, 2018
- Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer StrategyNutrients, 2018
- Histone Deacetylase Inhibitors as Anticancer DrugsInternational Journal of Molecular Sciences, 2017
- New and emerging HDAC inhibitors for cancer treatmentJCI Insight, 2014
- Sirtuins and Disease: The Road AheadFrontiers in Pharmacology, 2012
- A decade of exploring the cancer epigenome — biological and translational implicationsNature Reviews Cancer, 2011
- Mammalian Sirtuins: Biological Insights and Disease RelevanceAnnual review of pathology, 2010
- Epi-drugs to fight cancer: From chemistry to cancer treatment, the road aheadThe International Journal of Biochemistry & Cell Biology, 2009
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001